Inflection point: Our core medicines are all grown up!
Posted by
29-Oct-2012
The ‘cross-over’ had been anticipated and features in the financial results for the first nine months of 2012 which we have just published: Sales of our three core medicines – for rheumatoid arthritis, Crohn’s disease, epilepsy, and Parkinson’s disease – have eclipsed sales of UCB’s established epilepsy drug.
The three core medicines have reached more than 382,000 patients so far this year and delivered strong sales growth of 50%, clocking up combined net sales of EUR 665 million. This means we are on track to reach our ambition of treating more than 1.5 million patients and generating at least EUR 3.1 billion peak sales with these three products in the second half of this decade.
The well-established epilepsy therapy continues to help thousands of patients worldwide and reached net sales of EUR 652 million in the first nine months of 2012.
Overall for the first nine months of the year, UCB’s performance is in line with our expectations, recording total revenue of EUR 2,565 million (+5%).
Meanwhile, back in the ‘lab’…
So what about the "next" generation?
We continue to develop our core medicines and new treatments for conditions such as post-menopausal osteoporosis and lupus. Resting on our laurels has never been an option and we remain determined to deliver new products which offer breakthrough innovation to patients with severe diseases.
Looking to the near-term, UCB expects unchanged 2012 revenue to exceed EUR 3.2 billion, recurring EBITDA to be in the range of EUR 630 – 660 million, and core earnings per share to be approximately EUR 1.70.
For more details on any of this, don’t hesitate to get in touch antje.witte@ucb.com !
The three core medicines have reached more than 382,000 patients so far this year and delivered strong sales growth of 50%, clocking up combined net sales of EUR 665 million. This means we are on track to reach our ambition of treating more than 1.5 million patients and generating at least EUR 3.1 billion peak sales with these three products in the second half of this decade.
The well-established epilepsy therapy continues to help thousands of patients worldwide and reached net sales of EUR 652 million in the first nine months of 2012.
Overall for the first nine months of the year, UCB’s performance is in line with our expectations, recording total revenue of EUR 2,565 million (+5%).
Meanwhile, back in the ‘lab’…
So what about the "next" generation?
We continue to develop our core medicines and new treatments for conditions such as post-menopausal osteoporosis and lupus. Resting on our laurels has never been an option and we remain determined to deliver new products which offer breakthrough innovation to patients with severe diseases.
Looking to the near-term, UCB expects unchanged 2012 revenue to exceed EUR 3.2 billion, recurring EBITDA to be in the range of EUR 630 – 660 million, and core earnings per share to be approximately EUR 1.70.
For more details on any of this, don’t hesitate to get in touch antje.witte@ucb.com !
Leave a Comment